Xenetic Biosciences agreed to acquire Santersus AG in an all-stock transaction, with Santersus holders expected to own approximately 85% of Xenetic’s outstanding common stock after closing. The deal requires stockholder and Nasdaq approvals, while specified termination circumstances could trigger a $500,000 fee or expense reimbursements up to $300,000.
Key Highlights
- Certain Xenetic stockholders, including officers and directors, agreed to support the transaction and oppose competing Acquisition proposals.
- Specified termination circumstances could require Xenetic to pay Santersus a $500,000 fee.
- The combined company is expected to use the name Santersus Bio, Inc. and trade under the symbol SNTS.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) agreed on September 14, 2026, to acquire all issued Share Capital of Santersus AG in an all-stock transaction that would leave Santersus holders with approximately 85% of Xenetic’s outstanding common stock after closing. The expected ownership split assumes Net Cash of $0, with final percentages subject to adjustments under the agreement.
Share Exchange Sets Ownership Split Each Santersus ordinary share will be exchanged for
Xenetic common stock according to an exchange ratio, with fractional entitlements aggregated and rounded to whole shares. No fractional shares will be issued. Outstanding Santersus options, whether vested or unvested, will convert into Options for Xenetic common stock, with the share count and exercise price adjusted under the same ratio. Xenetic will also assume the Santersus Option Plan for those converted awards.
Approval Conditions Govern Closing
Xenetic must obtain stockholder approval for the share issuance, the resulting change of control, an increase in authorized shares, a name change to Santersus Bio, Inc. and related option or warrant-plan actions. Completion also requires an effective resale registration statement, Nasdaq approval for listing the issued shares, compliance with contractual covenants, accurate representations and warranties, and no law or order blocking the transaction. Certain Xenetic stockholders, including officers and directors, agreed to support the transaction and oppose competing acquisition proposals. Under specified termination conditions, Xenetic may owe Santersus $500,000, and either party may be required to reimburse expenses up to $300,000.



Please wait processing your request...